Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma

Leuk Lymphoma. 2010 Jul;51(7):1347-50. doi: 10.3109/10428194.2010.486091.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Immunoblastic Lymphadenopathy / drug therapy*
  • Lymphoma, T-Cell / drug therapy*
  • Salvage Therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Alemtuzumab